Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sensus Healthcare (SRTS) Gains from Sales and Divestitures (2017 - 2025)

Sensus Healthcare (SRTS) has 9 years of Gains from Sales and Divestitures data on record, last reported at $10000.0 in Q3 2025.

  • For Q3 2025, Gains from Sales and Divestitures fell 77.78% year-over-year to $10000.0; the TTM value through Sep 2025 reached $10000.0, down 77.78%, while the annual FY2024 figure was $72500.0, 10.27% up from the prior year.
  • Gains from Sales and Divestitures reached $10000.0 in Q3 2025 per SRTS's latest filing, roughly flat from $10000.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $72500.0 in Q4 2024 and bottomed at $8750.0 in Q2 2021.
  • Average Gains from Sales and Divestitures over 5 years is $28444.4, with a median of $15000.0 recorded in 2023.
  • Peak YoY movement for Gains from Sales and Divestitures: crashed 86.88% in 2021, then soared 71.43% in 2023.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $43750.0 in 2021, then fell by 5.71% to $41250.0 in 2022, then soared by 59.39% to $65750.0 in 2023, then increased by 10.27% to $72500.0 in 2024, then crashed by 86.21% to $10000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Sales and Divestitures were $10000.0 in Q3 2025, $10000.0 in Q2 2025, and $10000.0 in Q1 2025.